Patents by Inventor Ruchi Upmanyu

Ruchi Upmanyu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CETP inhibitors for therapeutic use
    Patent number: 11549142
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: January 10, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • CETP INHIBITORS FOR THERAPEUTIC USE
    Publication number: 20210017597
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: June 3, 2020
    Publication date: January 21, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-PIerre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • CETP inhibitors for therapeutic use
    Patent number: 10711303
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: July 14, 2020
    Assignee: Hoffman-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • CETP INHIBITORS FOR THERAPEUTIC USE
    Publication number: 20190226020
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: August 22, 2018
    Publication date: July 25, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • CETP INHIBITORS FOR THERAPEUTIC USE
    Publication number: 20180155784
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: January 22, 2018
    Publication date: June 7, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • Dalcetrapib for therapeutic use
    Patent number: 9909178
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: March 6, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu
  • GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY
    Publication number: 20160244826
    Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.
    Type: Application
    Filed: September 23, 2015
    Publication date: August 25, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Marie-Pierre Dube, Eric J. Niesor, Jean-Claude Tardif, Ruchi Upmanyu